S100A4 mediates endometrial cancer invasion and is a target of TGF-β1 signaling

Laboratory Investigation

Volumn 89, Issue 8, 2009, Pages 937-947

  Xie, Ran ^a   Schlumbrecht, Matthew P ^b   Shipley, Gregory L ^c   Xie, Susu ^a   Bassett, Roland L ^b   Broaddus, Russell R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cancer invasion; Endometrial cancer; Epithelial to mesenchymal transition; S100A family genes; S100A4

Indexed keywords

CALVASCULIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FIBROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 68149150752     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.52     Document Type: Article

References (60)

1. Robertson H, Ali S, McDonnell BJ, et al. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 2004;15:390-397.
2. Okada H, Danoff TM, Kalluri R, et al. Early role of Fsp1 in epithelialmesenchymal transformation. Am J Physiol 1997;273:F563-F574.
3. Rygiel KA, Robertson H, Marshall HL, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008;88:112-123.
4. Schneider M, Kostin S, Strom CC, et al. S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovasc Res 2007;75:40-50.
5. Lawson WE, Polosukhin VV, Zoia O, et al. Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:899-907.
6. Xie R, Loose DS, Shipley GL, et al. Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod Pathol 2007;20:1045-1054.
7. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003;60:540-551.
8. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004;322: 1111-1122.
9. Micci F, Teixeira MR, Haugom L, et al. Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes Cancer 2004;40:229-246.
10. Imazawa M, Hibi K, Fujitake S, et al. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. Anticancer Res 2005;25:1247-1250.
11. Weterman MA, Stoopen GM, van Muijen GN, et al. Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice. Cancer Res 1992;52:1291-1296.
12. Weterman MA, van Muijen GN, Bloemers HP, et al. Expression of calcyclin in human melanocytic lesions. Cancer Res 1993;53: 6061-6066.
13. Komatsu K, Kobune-Fujiwara Y, Andoh A, et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 2000;83:769-774.
14. Davies BR, O'Donnell M, Durkan GC, et al. Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol 2002;196:292-299.
15. Emberley ED, Niu Y, Njue C, et al. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res 2003;9:2627-2631.
16. Stulik J, Osterreicher J, Koupilova K, et al. The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis 1999;20: 1047-1054.
17. Nishiu M, Yanagawa R, Nakatsuka S, et al. Microarray analysis of gene-expression profiles in diffuse large B-cell lymphoma: identification of genes related to disease progression. Jpn J Cancer Res 2002;93:894-901.
18. Mori M, Shimada H, Gunji Y, et al. S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer. Oncol Rep 2004;11:1287-1293.
19. FIGO IFoGaO. Announcements. Gynecol Oncol 1989;35:125-127.
20. Callaerts-Vegh Z, Evans KL, Shipley GL, et al. Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery. Br J Pharmacol 2003;138:1505-1516.
21. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-3245.
22. Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998;4:230-241.
23. Galliher AJ, Neil JR, Schiemann WP. Role of transforming growth factor-beta in cancer progression. Future Oncol 2006;2:743-763.
24. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003;4:657-665.
25. Miettinen PJ, Ebner R, Lopez AR, et al. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994;127: 2021-2036.
26. Piek E, Moustakas A, Kurisaki A, et al. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999;112(Pt 24):4557-4568.
27. Bakin AV, Tomlinson AK, Bhowmick NA, et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000;275:36803-36810.
28. Xie L, Law BK, Aakre ME, et al. Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res 2003;5:R187-R198.
29. Kasai H, Allen JT, Mason RM, et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005;6:56.
30. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47-64.
31. Xie L, Law BK, Chytil AM, et al. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004;6:603-610.
32. Moustakas A, Heldin CH. Signaling networks guiding epithelialmesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007;98:1512-1520.
33. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-5774.
34. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype. Nat Rev Cancer 2007;7:415-428.
35. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 2007;39:2153-2160.
36. Yabushita H, Narumiya H, Hiratake K, et al. The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase. J Obstet Gynaecol Res 2000;26:163-170.
37. Krieg P, Schnapke R, Furstenberger G, et al. TGF-beta 1 and skin carcinogenesis: antiproliferative effect in vitro and TGF-beta 1 mRNA expression during epidermal hyperproliferation and multistage tumorigenesis. Mol Carcinog 1991;4:129-137.
38. Maehara Y, Kakeji Y, Kabashima A, et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999;17:607-614.
39. Gomella LG, Sargent ER, Wade TP, et al. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res 1989;49:6972-6975.
40. Gorsch SM, Memoli VA, Stukel TA, et al. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949-6952.
41. Walker RA, Dearing SJ. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 1992;28:641-644.
42. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993;143:381-389.
43. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-191.
44. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
45. Fuks F, Hurd PJ, Wolf D, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-4040.
46. Yoshida H, Broaddus R, Cheng W, et al. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelialmesenchymal transition. Cancer Res 2006;66:889-897.
47. Saleem M, Kweon MH, Johnson JJ, et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA 2006;103:14825-14830.
48. Ambartsumian NS, Grigorian MS, Larsen IF, et al. Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 1996;13:1621-1630.
49. Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-1636.
50. Giese A, Loo MA, Tran N, et al. Dichotomy of astrocytoma migration and proliferation. Int J Cancer 1996;67:275-282.
51. Merzak A, McCrea S, Koocheckpour S, et al. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer 1994;70:199-203.
52. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists? Am J Pathol 2002;160:7-13.
53. Watanabe Y, Usada N, Minami H, et al. Calvasculin, as a factor affecting the microfilament assemblies in rat fibroblasts transfected by src gene. FEBS Lett 1993;324:51-55.
54. Takenaga K, Nakamura Y, Sakiyama S, et al. Binding of pEL98 protein, an S100-related calcium-binding protein, to nonmuscle tropomyosin. J Cell Biol 1994;124:757-768.
55. Kriajevska MV, Cardenas MN, Grigorian MS, et al. Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem 1994;269: 19679-19682.
56. Li ZH, Bresnick AR. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res 2006;66:5173-5180.
57. Dulyaninova NG, Malashkevich VN, Almo SC, et al. Regulation of myosin-IIA assembly and Mts1 binding by heavy chain phosphorylation. Biochemistry 2005;44:6867-6876.
58. Tarabykina S, Griffiths TR, Tulchinsky E, et al. Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets 2007;7:217-228.
59. Bjornland K, Winberg JO, Odegaard OT, et al. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 1999;59: 4702-4708.
60. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signaling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011-1022.